Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of intravenous versus subcutaneous isatuximab with RVd in transplant-eligible newly diagnosed multiple myeloma
2022-000996-38Phase 3Active
- Sponsor
- Heidelberg University
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Heidelberg University. Primary endpoint: Rate of VGPR or better after induction therapy. Started Oct 2022; status: active.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-000996-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000996-38.